Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Expres2Ion Biotechnologies Aps manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently on file for the company. This single active case suggests a specific focus on a particular biological or pharmaceutical advancement. The current prosecution volume indicates a highly targeted approach to intellectual property protection in the life sciences sector.
The prosecution process is confined to a distinct examiner and 1 distinct art unit. This indicates that the technology is being reviewed by a specialized division of the patent office. KHOA NHAT TRAN is the busiest examiner, currently overseeing the busiest examiner pending office action. This examiner is the sole individual responsible for the company's current pending matters, which allows for a more direct and consistent technical exchange.
The presence of 1 distinct art unit and the pending office action suggests a low level of administrative complexity. Practitioners can focus their resources on addressing the specific technical issues raised by KHOA NHAT TRAN. Success in this matter will determine the current progress of the portfolio within the Biotechnology & Pharmaceuticals field, making the relationship with this specific examiner the central focus of the company's immediate patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421902 | PRODUCTION OF PROTEIN WITH HUMANIZED N-GLYCOSYLATION IN INSECT CELLS | TRAN, KHOA NHAT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17421902 | PRODUCTION OF PROTEIN WITH HUMANIZED N-GLYCOSYLATION IN INSECT CELLS | TRAN, KHOA NHAT | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17421902 | PRODUCTION OF PROTEIN WITH HUMANIZED N-GLYCOSYLATION IN INSECT CELLS | TRAN, KHOA NHAT | 1632 | §101§103§112 | Final Rejection | — | Pending | Jul 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExpres2Ion Biotechnologies Aps has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Khoa Nhat Tran has the most, with 1 of Expres2Ion Biotechnologies Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.